TNXP Quote, Financials, Valuation and Earnings

BioVie has a net margin of -856.24% compared to Tonix Pharmaceuticals Holding's net margin of --. Tonix Pharmaceuticals Holding's return on equity of -138.47% beat BioVie's return on equity of --.

Tonix Pharmaceuticals Holding has a consensus price target of $60.00, signalling upside risk potential of 212.66%. On the other hand BioVie has an analysts' consensus of $5.50 which suggests that it could grow by 414.02%. Given that BioVie has higher upside potential than Tonix Pharmaceuticals Holding, analysts believe BioVie is more attractive than Tonix Pharmaceuticals Holding.

Tonix Pharmaceuticals Holding has a beta of 1.627, which suggesting that the stock is 62.658% more volatile than S&P 500. In comparison BioVie has a beta of 1.180, suggesting its more volatile than the S&P 500 by 18.039%.

Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioVie offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. BioVie pays out -- of its earnings as a dividend.

Tonix Pharmaceuticals Holding quarterly revenues are $2.6M, which are larger than BioVie quarterly revenues of --. Tonix Pharmaceuticals Holding's net income of -$22.1M is lower than BioVie's net income of -$7.1M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while BioVie's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 2.41x versus -- for BioVie. Usually stocks with elevated PS ratios are considered overvalued.

Cognition Therapeutics has a net margin of -856.24% compared to Tonix Pharmaceuticals Holding's net margin of --. Tonix Pharmaceuticals Holding's return on equity of -138.47% beat Cognition Therapeutics's return on equity of --.

Tonix Pharmaceuticals Holding has a consensus price target of $60.00, signalling upside risk potential of 212.66%. On the other hand Cognition Therapeutics has an analysts' consensus of $4.60 which suggests that it could grow by 1276.57%. Given that Cognition Therapeutics has higher upside potential than Tonix Pharmaceuticals Holding, analysts believe Cognition Therapeutics is more attractive than Tonix Pharmaceuticals Holding.

Tonix Pharmaceuticals Holding has a beta of 1.627, which suggesting that the stock is 62.658% more volatile than S&P 500. In comparison Cognition Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cognition Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. Cognition Therapeutics pays out -- of its earnings as a dividend.

Tonix Pharmaceuticals Holding quarterly revenues are $2.6M, which are larger than Cognition Therapeutics quarterly revenues of --. Tonix Pharmaceuticals Holding's net income of -$22.1M is lower than Cognition Therapeutics's net income of -$8.5M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while Cognition Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 2.41x versus -- for Cognition Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Cocrystal Pharma has a net margin of -856.24% compared to Tonix Pharmaceuticals Holding's net margin of --. Tonix Pharmaceuticals Holding's return on equity of -138.47% beat Cocrystal Pharma's return on equity of --.

Tonix Pharmaceuticals Holding has a consensus price target of $60.00, signalling upside risk potential of 212.66%. On the other hand Cocrystal Pharma has an analysts' consensus of $8.33 which suggests that it could grow by 432.48%. Given that Cocrystal Pharma has higher upside potential than Tonix Pharmaceuticals Holding, analysts believe Cocrystal Pharma is more attractive than Tonix Pharmaceuticals Holding.

Tonix Pharmaceuticals Holding has a beta of 1.627, which suggesting that the stock is 62.658% more volatile than S&P 500. In comparison Cocrystal Pharma has a beta of 2.127, suggesting its more volatile than the S&P 500 by 112.692%.

Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cocrystal Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. Cocrystal Pharma pays out -- of its earnings as a dividend.

Tonix Pharmaceuticals Holding quarterly revenues are $2.6M, which are larger than Cocrystal Pharma quarterly revenues of --. Tonix Pharmaceuticals Holding's net income of -$22.1M is lower than Cocrystal Pharma's net income of -$4.9M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while Cocrystal Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 2.41x versus 7.91x for Cocrystal Pharma. Usually stocks with elevated PS ratios are considered overvalued.

PDS Biotechnology has a net margin of -856.24% compared to Tonix Pharmaceuticals Holding's net margin of --. Tonix Pharmaceuticals Holding's return on equity of -138.47% beat PDS Biotechnology's return on equity of --.

Tonix Pharmaceuticals Holding has a consensus price target of $60.00, signalling upside risk potential of 212.66%. On the other hand PDS Biotechnology has an analysts' consensus of $7.50 which suggests that it could grow by 481.4%. Given that PDS Biotechnology has higher upside potential than Tonix Pharmaceuticals Holding, analysts believe PDS Biotechnology is more attractive than Tonix Pharmaceuticals Holding.

Tonix Pharmaceuticals Holding has a beta of 1.627, which suggesting that the stock is 62.658% more volatile than S&P 500. In comparison PDS Biotechnology has a beta of 1.397, suggesting its more volatile than the S&P 500 by 39.741%.

Tonix Pharmaceuticals Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PDS Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tonix Pharmaceuticals Holding pays -- of its earnings as a dividend. PDS Biotechnology pays out -- of its earnings as a dividend.

Tonix Pharmaceuticals Holding quarterly revenues are $2.6M, which are larger than PDS Biotechnology quarterly revenues of --. Tonix Pharmaceuticals Holding's net income of -$22.1M is lower than PDS Biotechnology's net income of -$10.7M. Notably, Tonix Pharmaceuticals Holding's price-to-earnings ratio is -- while PDS Biotechnology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tonix Pharmaceuticals Holding is 2.41x versus -- for PDS Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.